• Explore /
  • Poster
  • / Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials.

Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials.

Abstract Poster

Authors

null

Meena Venkatachalam

Parexel, Waltham, MA

Meena Venkatachalam , David D. Stenehjem , Guilhem Pietri , John R. Penrod , Beata Korytowsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research and Quality of Care

Track

Health Services Research and Quality of Care

Sub Track

Value/Cost of Care

Clinical Trial Registration Number

NCT01642004, NCT01673867

Citation

J Clin Oncol 34, 2016 (suppl; abstr 6617)

DOI

10.1200/JCO.2016.34.15_suppl.6617

Abstract #

6617

Poster Bd #

100

Abstract Disclosures

Similar Posters

First Author: Helmy M. Guirgis

First Author: Hossein Borghaei

First Author: Jonathan Wade Goldman

First Author: Thierry Landre